

PART VI: SUMMARY OF THE RISK MANAGEMENT PLAN

Summary of risk management plan for *Boostrix-Polio*

This is a summary of the risk management plan (RMP) for *Boostrix-Polio*. The RMP details important risks of *Boostrix-Polio*, how these risks can be minimised, and how more information will be obtained about *Boostrix-Polio*'s risks and uncertainties (missing information).

Boostrix-Polio's summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how *Boostrix-Polio* should be used.

I The medicine and what it is used for

Boostrix-Polio is authorised for booster vaccination against diphtheria, tetanus, pertussis and poliomyelitis of individuals from the age of three years onwards (see SmPC for the full indication). It contains diphtheria, tetanus, pertussis (acellular component) and poliomyelitis (inactivated) vaccine (adsorbed) as the active substance and it is given by deep intramuscular injection preferably in the deltoid region.

II Risks associated with the medicine and activities to minimise or further characterise the risks

Important risks of *Boostrix-Polio*, together with measures to minimise such risks and the proposed studies for learning more about *Boostrix-Polio*'s risks, are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine's packaging;
- The authorised pack size — the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status — the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimise its risks.

Together, these measures constitute *routine risk minimisation* measures.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed so that immediate action can be taken as necessary. These measures constitute *routine pharmacovigilance activities*.

If important information that may affect the safe use of *Boostrix-Polio* is not yet available, it is listed under 'missing information' below.

II.A List of important risks and missing information

Important risks of *Boostrix-Polio* are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely administered. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of Polio. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine);

List of important risks and missing information	
Important identified risks	<ul style="list-style-type: none"> • None
Important potential risks	<ul style="list-style-type: none"> • Blunting (Immune interference)
Missing information	<ul style="list-style-type: none"> • Tdap/Tdap-IPV use in Pregnant women • Tdap waning of immunity

II.B Summary of important risks

Important potential risk: Blunting (Immune interference)	
Evidence for linking the risk to the medicine	<p>A potential concern raised was whether antibodies elicited by Tdap/Tdap-IPV vaccination during pregnancy and transferred to the foetus could interfere with the immune response to the paediatric vaccines, an outcome referred to as “blunting”. This effect was previously described in infants from pregnant women with high antibody titers following whole cell pertussis vaccination.</p> <p>There is scientific evidence showing that high concentrations of maternally acquired antibodies (from pre-pregnancy vaccination or natural infection) interfere with the infant’s immune response to vaccination. Nowadays, in the context of dTpa maternal recommendation, higher levels of diphtheria, tetanus and pertussis antibodies were shown to be transferred to the newborn during pregnancy resulting potentially in higher impact on infant vaccination series, as compared with no dTpa /dTpa-IPV vaccination during pregnancy [Maertens K, 2016a; Maertens K, 2016b; Maertens K, 2017]. However currently the clinical significance of blunting is unknown and more scientific evidence is still required from large clinical studies to assess the extent and clinical relevance of blunting on infant vaccination series.</p> <p>The mechanisms behind this phenomenon, as well as the factors that trigger it, are not yet fully understood.</p>
Risk factors and risk groups	As pertussis has a higher mortality and morbidity among children less than one year that have not yet received all childhood vaccination series, this subpopulation would be considered at higher risk.
Risk minimisation measures	<p>Routine risk minimisation measures:</p> <p>To inform the prescriber about the limited clinical information regarding the use of <i>Boostrix</i> in pregnancy and its potential consequence in the offspring, the approved section 4.6 of the EU SmPC “Fertility, pregnancy and lactation” reads as follows:</p> <p><i>“Limited data indicate that maternal antibodies may reduce the magnitude of the immune response to some vaccines in infants born from mothers vaccinated with Boostrix-Polio during pregnancy. The clinical relevance of this observation is unknown.”</i></p> <p>Additional risk minimisation measures:</p> <p>Not required at this moment</p>

Additional pharmacovigilance activities	<p>Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection:</p> <ul style="list-style-type: none">• Plan to monitor scientific evidence on the effectiveness of pertussis maternal immunization to prevent the disease in infants and on the impact of maternal immunization programs on pertussis epidemiology. <p>Additional pharmacovigilance activities:</p> <p>There are no specific post-authorization safety studies for <i>Boostrix-Polio</i>, but given the shared antigens, the post-authorization studies of <i>Boostrix</i> are included here:</p> <p><u>Ongoing</u></p> <ul style="list-style-type: none">• DTPA (<i>BOOSTRIX</i>)-048 PRI (201330)• DTPA (<i>BOOSTRIX</i>)-049 BST: 048 (201334)
---	--

Missing Information: Tdap/Tdap-IPV use in pregnant women	
Evidence for linking the risk to the medicine	<p>Limited data on the safety or immunogenicity of <i>Boostrix-Polio</i> during pregnancy or lactation are available. It is generally accepted that inactivated vaccines pose no risk to the pregnant or lactating women and their child.</p> <p>In response to pertussis outbreaks, the US was the first country (in 2011) to recommend the use of Tdap in pregnant women who had not been previously vaccinated with Tdap in adulthood. This recommendation updated in 2013 states that women should receive a Tdap vaccination during each pregnancy, irrespective of the woman's prior history of vaccination with Tdap [CDC, 2013] as anti-pertussis antibody levels wane substantially during the first year after vaccination.</p> <p>Following the initial recommendation in the US by the Advisory Committee on Immunization Practices (ACIP) in 2011 [ACIP, 2012], Tdap immunization programs for pregnant women have been implemented in more than 34 countries worldwide. Until very recently, no published or unpublished clinical data on immunogenicity, efficacy, or effectiveness in pregnant women were available since pregnant women have been routinely excluded from clinical trials. However, there are no specific safety concerns or expectations of harm, and use in pregnancy is not contraindicated. But the use of Tdap in pregnancy is considered as missing information regarding the safety profile of Tdap in pregnant women and the effect of it on the fetus.</p>
Risk factors and risk groups	Pregnant and lactating women and their offspring.

Risk minimisation measures	<p>Routine risk minimisation measures:</p> <p>To inform the prescriber about the current safety information regarding the use of <i>Boostrix-Polio</i> in pregnancy, the approved section 4.6 of the EU SmPC “Fertility, pregnancy and lactation” reads as follows:</p> <p>Pregnancy:</p> <p><i>Safety data from a prospective observational study where Boostrix (dTpa component of Boostrix-Polio) was administered to pregnant women during the third trimester (793 pregnancy outcomes) as well as data from passive surveillance where pregnant women were exposed to Boostrix-Polio or to Boostrix in the 3rd and 2nd trimester have shown no vaccine related adverse effect on pregnancy or on the health of the foetus/newborn child.</i></p> <p><i>The use of Boostrix-Polio may be considered during the third trimester of pregnancy.</i></p> <p><i>Human data from prospective clinical studies on the use of Boostrix-Polio during the first and second trimester of pregnancy are not available. However, as with other inactivated vaccines, it is not expected that vaccination with Boostrix-Polio harms the foetus at any trimester of pregnancy. The benefits versus the risks of administering Boostrix-Polio during pregnancy should be carefully evaluated.</i></p> <p><i>Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, parturition or post-natal development (see section 5.3 of EU SmPC).</i></p> <p><i>Limited data indicate that maternal antibodies may reduce the magnitude of the immune response to some vaccines in infants born from mothers vaccinated with Boostrix-Polio during pregnancy. The clinical relevance of this observation is unknown.</i></p> <p>Breastfeeding:</p> <p><i>The effect of administration of Boostrix-Polio during lactation has not been assessed. Nevertheless, as Boostrix-Polio contains toxoids or inactivated antigens, no risk to the breastfed infant should be expected. The benefits versus the risk of administering Boostrix-Polio to breastfeeding women should carefully be evaluated by the healthcare providers.</i></p> <p>Fertility:</p> <p><i>No human data from prospective clinical studies are available. Animal studies do not indicate direct or indirect harmful effects with respect to female fertility (see section 5.3 of EU SmPC).</i></p> <p>Additional risk minimisation measures:</p> <p>Not required at this moment</p>
----------------------------	--

Additional pharmacovigilance activities	<p>Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection:</p> <ul style="list-style-type: none">• None <p>Additional pharmacovigilance activities:</p> <p>There are no specific post-authorization safety studies for <i>Boostrix-Polio</i>, but given the shared antigens, the post-authorization studies of <i>Boostrix</i> are included here:</p> <p><u>Ongoing</u></p> <ul style="list-style-type: none">• DTPA (<i>BOOSTRIX</i>)-047 (116945)• DTPA (<i>BOOSTRIX</i>)-048 PRI (201330)• DTPA (<i>BOOSTRIX</i>)-049 BST: 048 (201334)• EPI-PERTUSSIS-028 VS US PR (201327) <p><u>Completed:</u></p> <ul style="list-style-type: none">• EPI-PERTUSSIS-037 VS BR (203153)• EPI-PERTUSSIS-025 VS NZ SUPP (201024)
---	--

Missing information: Tdap waning of immunity	
Evidence for linking the risk to the medicine	<p>Recently a resurgence of pertussis has been observed in various countries, including those considered to achieve a high coverage of Tdap and full antigen content-DTPa. This has included children less than one year of age, who are at highest risk of mortality and sequelae from pertussis. Whilst previously adolescents and adults rarely presented with pertussis, cases in this age group are also now increasingly being detected suggesting an epidemiological shift towards these older ages, especially in United States, Europe and Australia [ACIP, 2013, CDC, 2013]. Waning of immunity by acellular pertussis vaccines has been proposed as a potential explanatory factor for these outbreaks. Large observational studies have demonstrated that Tdap protection wanes within 2-4 years in adolescents [Acosta AM, 2015] and does not protect against outbreaks. Furthermore, conclusions from systematic reviews show that the short-term protective effect against WHO-defined pertussis in young children was lower for currently available acellular pertussis vaccines than whole cell pertussis vaccines [Fulton TR, 2016].</p>
Risk factors and risk groups	<p>The waning of immunity could lead to an increase of susceptible individuals and favor the occurrence of pertussis outbreaks, therefore increasing the burden of disease by both morbidity and mortality increase.</p>
Risk minimisation measures	<p>Routine risk minimisation measures:</p> <p>Section 4.4 ‘Special warnings and precautions for use’ of the EU SmPC states: <i>“As with any vaccine, a protective immune response may not be elicited in all vaccinees”</i></p> <p>Section 4.2 “posology” of the EU SmPC: <i>“Repeat vaccination against diphtheria, tetanus, pertussis and poliomyelitis should be performed at intervals as per official recommendations”.</i></p> <p>Additional risk minimisation measures:</p> <p>Not required at this moment</p>

<p>Additional pharmacovigilance activities</p>	<p>Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Targeted follow up questionnaire for vaccination failure / lack of efficacy in DTP vaccines</p> <p>Additional pharmacovigilance activities: None</p> <p>See section II.C of this summary for an overview of the post-authorisation development plan.</p>
--	---

II.C Post-authorisation development plan

II.C.1 Studies which are conditions of the marketing authorisation

There are no studies which are conditions of the marketing authorisation or specific obligation of *Boostrix-Polio*.

II.C.2 Other studies in post-authorisation development plan

There are no post-authorization studies with *Boostrix-Polio*. The clinical studies with *Boostrix-Polio* are already concluded at data lock point of this report. The studies listed below are part of the pharmacovigilance plan of *Boostrix*, but as the antigens and components of *Boostrix* and *Boostrix-Polio* are the same besides the *Poliomyelitis* antigens, GSK considers this information important regarding both products.

Study/Activity (including study number)	Objectives	Safety concerns/efficacy issue addressed	Status	Planned date for submission of (interim and) final study results
DTPA (<i>BOOSTRIX</i>)-047] (116945)	A Phase IV, observer-blind, randomised, cross-over, placebo-controlled, multicentre study to assess the immunogenicity and safety of a single dose of <i>Boostrix</i> in pregnant women	Tdap use in pregnant women (missing information)	Active	Forecast dates as regards the Final report Submission: Q4 2019
DTPA (<i>BOOSTRIX</i>)-048 PRI (201330)	A phase IV, open-label, non-randomised, multicentre study to assess the immunogenicity and safety of <i>Infanrix hexa</i> administered as primary vaccination in healthy infants	Blunting (potential risk)	Active	Forecast dates as regards the Final report Submission: Q4 2019

	born to mothers vaccinated with <i>Boostrix</i> during pregnancy or immediately post-delivery.			
DTPA (<i>BOOSTRIX</i>)- 049 BST: 048 (201334)	A phase IV, open-label, non-randomised, multicentre study to assess the immunogenicity and safety of a booster dose of <i>Infanrix hexa</i> in healthy infants born to mothers vaccinated with <i>Boostrix</i> during pregnancy or immediately post-delivery.	Blunting (potential risk)	Active	Forecast dates as regards the Final report Submission: Q3 2020
EPI- PERTUSSIS- 028 VS US PR also referred as the <i>Boostrix</i> US pregnancy Registry.	A prospective, exploratory, cohort study to detect and describe any abnormal pregnancy outcomes in women intentionally or unintentionally vaccinated with <i>Boostrix</i> during pregnancy or within 28 days preceding conception.	Tdap use in pregnant women (missing information)	Active	Final report expected in Q3 2020, Latest interim report (DLP: 2 August 2017) available in Annex 7.
EPI- PERTUSSIS- 025 VS NZ SUPP (201024)	A three-component observational study that	Tdap use in pregnant women (missing information)	Completed	Q2 2018

also referred as the Pertussis in Pregnancy Safety (PIPS) study.	collected data prospectively (study component 2 and study component 3) and retrospectively (study component 1) to assess the safety profile of <i>Boostrix</i> when used during a maternal immunisation program funded by the New Zealand Ministry of Health.			
EPI- PERTUSSIS- 037 VS BR (203153)	A post-marketing, observational, retrospective, cohort study to assess the safety of <i>Refortrix</i> (Tdap) when administered during pregnancy in a maternal immunization program in Brazil.	Tdap use in pregnant women (missing information)	Completed	Q2 2018

REFERENCES

Abu Raya B, Bamberger E, Almog M, Peri R, Srugo I, Kessel A. Immunization of pregnant women against pertussis: the effect of timing on antibody avidity. *Vaccine*. 2015 Apr 15;33(16):1948-52.

Abu Raya B, Srugo I, Kessel A, Peterman M, Bader D, Gonen R, Bamberger E. The effect of timing of maternal tetanus, diphtheria, and acellular pertussis (Tdap) immunization during pregnancy on newborn pertussis antibody levels - a prospective study. *Vaccine*. 2014 Oct 7;32(44):5787-93.

Abu Raya B, Srugo I, Kessel A, Peterman M, Bader D, Peri R, Ashtamker N, Gonen R, Bamberger E. The induction of breast milk pertussis specific antibodies following gestational tetanus-diphtheria-acellular pertussis vaccination. *Vaccine*. 2014b Sep 29;32(43):5632-7.

Acosta AM, DeBolt C, Tasslimi A, Lewis M, Stewart LK, Misegades LK, Messonnier NE, Clark TA, Martin SW, Patel M. Tdap vaccine effectiveness in adolescents during the 2012 Washington state pertussis epidemic. *Pediatrics*. 2015; 135(6): 981-9.

Advisory Committee on Immunization Practices (ACIP), Meeting of the Centers for Disease Control and Prevention (CDC). June 19-20, 2013. Website [.cdc.gov/vaccines/acip/meetings/meetings-info.html](http://www.cdc.gov/vaccines/acip/meetings/meetings-info.html) (accessed on 28 of August 2013). Website [.cdc.gov/vaccines/acip/meetings/slides-jun-2013.html](http://www.cdc.gov/vaccines/acip/meetings/slides-jun-2013.html) (accessed on 28th of August 2013)

Advisory Committee on Immunization Practices (ACIP), 2012. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant women--Advisory Committee on Immunization Practices (ACIP), 2012. *MMWR Morb Mortal Wkly Rep*. 2013 Feb 22;62(7):131-5. Website : [.cdc.gov/vaccines/acip/meetings/downloads/min-archive/min-feb13.pdf](http://www.cdc.gov/vaccines/acip/meetings/downloads/min-archive/min-feb13.pdf) (accessed on 28th of August 2013)

American College of Obstetricians and Gynecologists (ACOG). Update on immunization and pregnancy: tetanus, diphtheria, and pertussis vaccination. Committee Opinion No. 566. *Obstet Gynecol* 2013; 121:1411–4. Reaffirmed 2015. Website: 'internet site'. [.acog.org/Resources-And-Publications/Committee-Opinions/Committee-on-Obstetric-Practice/Update-on-Immunization-and-Pregnancy-Tetanus-Diphtheria-and-Pertussis-Vaccination](http://www.acog.org/Resources-And-Publications/Committee-Opinions/Committee-on-Obstetric-Practice/Update-on-Immunization-and-Pregnancy-Tetanus-Diphtheria-and-Pertussis-Vaccination). Accessed 1 August 2016

Amirthalingam G, Andrews N, Campbell H, Ribeiro S, Kara E, Donegan K, Fry NK, Miller E, Ramsay M. Effectiveness of maternal pertussis vaccination in England: an observational study. *Lancet*. 2014 Oct 25;384(9953):1521-8.

Amirthalingam G, Campbell H, Ribeiro S, Fry NK, Ramsay M, Miller E, Andrews N. Sustained Effectiveness of the Maternal Pertussis Immunization Program in England 3 Years Following Introduction. *Clin Infect Dis*. 2016 Dec 1;63(suppl 4):S236-S243.

Anderson RM, May RM. Immunisation and herd immunity. *Lancet* 1990;335(8690):641–645

Anpassung der Impfeempfehlung gegen Pertussis 2013 (AIP). Available at: 'internet site' 'Internet site'://bag.admin.ch/dam/bag/de/dokumente/mt/infektionskrankheiten/keuchhusten/bag-bulletin-anpass-impf-empf-pertussis-jugend-saeug-schwanger.pdf.download.pdf/jugend-schwang-etc-d.pdf (accessed Nov 2016)

Augustynowicz E, Lutynska A, Piotrowska A, Paradowska-Stankiewicz I. The safety and effectiveness of vaccination against influenza and pertussis in pregnant women. *Przegl Epidemiol.* 2017;71(1):55-67.

Australian Technical Advisory Group on Immunisation (ATAGI). In: The Australian Immunisation Handbook 10th edn. 'internet site'.immunise.health.gov.au/internet/immunise/publishing.nsf/Content/Handbook10-home~handbook10part4~handbook10-4-12. Accessed July 2015

Barret AS, Ryan A, Breslin A, Cullen L, Murray A, Grogan J, Bourke S, Cotter S.. Pertussis outbreak in northwest Ireland, January - June 2010. *Euro Surveill* 2010;15(35):pii=19654.

Baxter R, Bartlett J, Fireman B, Lewis E, Klein NP. Effectiveness of Vaccination During Pregnancy to Prevent Infant Pertussis. *Pediatrics.* 2017 May;139(5). pii: e20164091.

Bellido-Blasco J, Guiral-Rodrigo S, Míguez-Santiyán A, Salazar-Cifre A, González-Morán F. A case-control study to assess the effectiveness of pertussis vaccination during pregnancy on newborns, Valencian community, Spain, 1 March 2015 to 29 February 2016. *Euro Surveill.* 2017 Jun 1;22(22). pii: 30545.

Bento AI, King AA, Rohani P. Maternal pertussis immunisation: clinical gains and epidemiological legacy. *Euro Surveill.* 2017 Apr 13;22(15). pii: 30510. doi:10.2807/1560-7917.ES.2017.22.15.30510.

Berenson AB, Hirth JM, Rahman M, Laz TH, Rupp RE, Sarpong KO. Maternal and infant outcomes among women vaccinated against pertussis during pregnancy. *Hum Vaccin Immunother.* 2016 Mar 22:1-7.

Bethell DB, Hien TT. Chapter 7.11.1: Diphtheria. In: Warrell DA, Cox TM, Firth JD, eds. *Oxford Textbook of Medicine.* 5th edn. Oxford: Oxford University Press; 2010:453–456.

Bisgard KM, Pascual FB, Ehresmann KR, *et al.*. Infant pertussis: who was the source? *Pediatr Infect Dis J* 2004;23(11):985–989.

Bleck TP. *Clostridium tetani* (Tetanus). In: Mandell GL, Bennett JE, Dolin R, eds. *Principles and Practice of Infectious Diseases.* 6th edn. Philadelphia: Elsevier Churchill Livingstone; 2005:2817–2822.

Bolotin S, Harvill ET, Crowcroft NS. What to do about pertussis vaccines? Linking what we know about pertussis vaccine effectiveness, immunology and disease transmission to create a better vaccine. *Pathog Dis.* 2015. Nov;73(8):ftv057.

Briere EC, Pondo T, Schmidt M, Skoff T, Shang N, Naleway A, Martin S, Jackson ML. Assessment of Tdap Vaccination Effectiveness in Adolescents in Integrated Health-Care Systems. *J Adolesc Health*. 2018 Mar 15. pii: S1054-139X(18)30005-3.doi: 10.1016/j.jadohealth.2017.12.011

California Department of Public Health (CDPH). Pertussis Report. August 10, 2011. 2011. 'internet site'. cdph.ca.gov/programs/immunize/Documents/PertussisReport2011-08-10.pdf. Accessed 7 February 2013

Cabrera-Maqueda JM, Hernández-Clares R, Baidez-Guerrero AE, Pío-Rendón JIB, Fernández JJM. Optic neuritis in pregnancy after Tdap vaccination: Report of two cases. *Clin Neurol Neurosurg*. 2017a Sep;160:116-118.

Cabrera-Maqueda JM, Ester BGA, Clares RH, Luna FR, Ana MO, Lallana JM, Fernandez JM. Optic neuritis during pregnancy following TDPA vaccination: Report of two cases. *Neurology* 2017b: 88 (16).

Caboré RN, Maertens K, Dobby A, Leuridan E, Van Damme P, Huygen K. Influence of maternal vaccination against diphtheria, tetanus, and pertussis on the avidity of infant antibody responses to a pertussis containing vaccine in Belgium. *Virulence*. 2017 Oct 3;8(7):1245-1254.

Calvert A, Jones CE. Placental transfer of antibody and its relationship to vaccination in pregnancy. *Curr Opin Infect Dis*. 2017 Jun;30(3):268-273.

Celentano LP, Massari M, Paramatti D, Salmaso S, Tozzi AE; EUVAC-NET Group. Resurgence of pertussis in Europe. *Pediatr Infect Dis J* 2005;24 (9):761–765.

Centers for Disease Control and Prevention (CDC), 1994. "International Notes Certification of Poliomyelitis Eradication – the Americas, 1994". *Morbidity and Mortality Weekly Report (Centers for Disease Control and Prevention)* 43 (39): 720–722.

Centers for Disease Control and Prevention (CDC). Chapter 15: Pertussis. In: Atkinson W, Wolfe S, Hamborsky J, eds. *Epidemiology and Prevention of Vaccine-Preventable Diseases [Pink Book]*. 12th edn. Washington, DC: Public Health Foundation; 2012b:215–232. Website.cdc.gov/vaccines/pubs/pinkbook/downloads/pert.pdf. Accessed February 2013.

Centers for Disease Control and Prevention (CDC). Chapter 17: Poliomyelitis. In: Atkinson W, Wolfe S, Hamborsky J, eds. *Epidemiology and Prevention of Vaccine-Preventable Diseases [Pink Book]*. 12th edn. Washington, DC: Public Health Foundation; 2012d:249–262. 'internet site'. cdc.gov/vaccines/pubs/pinkbook/downloads/polio.pdf. Accessed 7 February 2013

Centers for Disease Control and Prevention (CDC). Chapter 20: Tetanus. In: Atkinson W, Wolfe S, Hamborsky J, eds. *Epidemiology and Prevention of Vaccine-Preventable Diseases [Pink Book]*. 12th edn. Washington, DC: Public Health Foundation; 2012c:291–300. Website.cdc.gov/vaccines/pubs/pinkbook/downloads/tetanus.pdf. Accessed February 2013.

Centers for Disease Control and Prevention (CDC). Chapter 6: Diphtheria. In: Atkinson W, Wolfe S, Hamborsky J, eds. *Epidemiology and Prevention of Vaccine-Preventable Diseases*

[Pink Book]. 12th edn. Washington, DC: Public Health Foundation; 2012a:75–86. Website [.cdc.gov/vaccines/pubs/pinkbook/downloads/dip.pdf](http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/dip.pdf). Accessed February 2013.

Centers for Disease Control and Prevention (CDC). Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (dTpa) in pregnant women and persons who have or anticipate having close contact with an infant aged 12 months - Advisory Committee on Immunization Practices (ACIP), 2011. *MMWR Morb Mortal Wkly Rep.* 2011 Oct 21;60(41):1424-6

Centers for Disease Control and Prevention (CDC). Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (dTpa) in pregnant women - Advisory Committee on Immunization Practices (ACIP), 2012a. *MMWR Morb Mortal Wkly Rep.* 2013 Feb 22;62(7):131-5.

Centers for Disease Control and Prevention (CDC). Pertussis vaccination: use of acellular pertussis vaccines among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR* 1997;46(No. RR-7):1–25.

Centers for Disease Control and Prevention (CDC). Pertussis treatment , 2012: source Website: [.cdc.gov/pertussis/clinical/treatment.html](http://www.cdc.gov/pertussis/clinical/treatment.html) Accessed 20 September 2013

Choi WS, Choi JH, Kwon KT, Seo K, Kim MA, Lee SO, Hong YJ, Lee JS, Song JY, Bang JH, Choi HJ, Choi YH, Lee DG, Cheong HJ; Committee of Adult Immunization; Korean Society of Infectious Diseases.. Revised Adult Immunization Guideline Recommended by the Korean Society of Infectious Diseases, 2014. *Infect Chemother* 2015; 47: 68–79. DOI: 10.3947/ic.2015.47.1.68.

Choi YH, Campbell H, Amirthalingam G, van Hoek AJ, Miller E. Investigating the pertussis resurgence in England and Wales, and options for future control. *BMC Med.* 2016 Sep 1;14(1):121.

Clarke KEN. Review of the Epidemiology of Diphtheria 2000-2016. World Health Organization. 2017. Website 'Internet site': [://who.int/immunization/sage/meetings/2017/april/1_Final_report_Clarke_april3.pdf](http://who.int/immunization/sage/meetings/2017/april/1_Final_report_Clarke_april3.pdf)

Dabrera G, Amirthalingam G, Andrews N, Campbell H, Ribeiro S, Kara E, Fry NK, Ramsay M. A case-control study to estimate the effectiveness of maternal pertussis vaccination in protecting newborn infants in England and Wales, 2012-2013. *Clin Infect Dis* 2015;60(3):333–337.

Datwani H, Moro PL, Harrington T, Broder KR. Chorioamnionitis following vaccination in the Vaccine Adverse Event Reporting System. *Vaccine.* 2015;33(27):3110-3.

de Greeff SC, Mooi FR, Westerhof A, Verbakel JM, Peeters MF, Heuvelman CJ, Notermans DW, Elvers LH, Schellekens JF, de Melker HE. Pertussis disease burden in the household: how to protect young infants. *Clin Infect Dis* 2010; 50:1339-45

DeSilva M, Vazquez-Benitez G, Nordin JD, Lipkind HS, Romitti PA, DeStefano F, Kharbanda EO. Tdap Vaccination During Pregnancy and Microcephaly and Other Structural Birth Defects in Offspring. *JAMA*. 2016 Nov 1;316(17):1823-1825.

DeSilva M, Vazquez-Benitez G, Nordin JD, Lipkind HS, Klein NP, Cheetham TC, Naleway AL, Hambidge SJ, Lee GM, Jackson ML, McCarthy NL, Kharbanda EO. Maternal Tdap vaccination and risk of infant morbidity. *Vaccine*. 2017 Jun 22;35(29):3655-3660.

De Schutter S, Maertens K, Baerts L, De Meester I, Van Damme P, Leuridan E. Quantification of vaccine-induced antipertussis toxin secretory IgA antibodies in breast milk: comparison of different vaccination strategies in women. *Pediatr Infect Dis J*. 2015 Jun;34(6):e149-52.

Domenech de Cellès M, Magpantay FMG, King AA, Rohani P. The impact of past vaccination coverage and immunity on pertussis resurgence. *Sci Transl Med*. 2018 Mar 28;10(434).

Domenech de Cellès M, Magpantay FM, King AA, Rohani P. The pertussis enigma: reconciling epidemiology, immunology and evolution. *Proc Biol Sci*. 2016 Jan 13;283(1822).

Donegan K, King B, Bryan P. Safety of pertussis vaccination in pregnant women in UK: observational study. *BMJ*. 2014 Jul 11;349:355.

Eberhardt CS, Blanchard-Rohner G, Lemaître B, Maternal Immunization Earlier in Pregnancy Maximizes Antibody Transfer and Expected Infant Seropositivity Against Pertussis. *Clin Infect Dis*. 2016;62(7):829-36.

ECDC (European Center for Disease Prevention and Control). Annual epidemiological report: Reporting on 2010 surveillance data and 2011 epidemic intelligence data, 2012. Website ecdc.europa.eu/en/publications/Publications/Annual-Epidemiological-Report-2012.pdf. Accessed April 2013.

ECDC (European Center for Disease Prevention and Control). annual Epidemiological report for 2015 - Pertussis. Website: 'Internet site'://ecdc.europa.eu/sites/portal/files/documents/AER_for_2015-pertussis.pdf. Accessed April 2018

ECDC (European Center for Disease Prevention and Control). Vaccination Schedules. Available at: 'internet site' 'Internet site'://vaccine-schedule.ecdc.europa.eu/Pages/Scheduler.aspx (accessed Oct 2017)

Edwards KM, Decker MD. Pertussis vaccines. In: Plotkin SL, Orenstein WA, Offit PA, eds. *Vaccines*. 5th edn. Philadelphia: Saunders Elsevier; 2008:467–517.

El Salvador, Ministry of Health (ESMoH). Immunization program 2016. Available at: 'internet site' 'Internet site'://salud.gob.sv/esquema-nacional-de-vacunacion-el-salvador-2016/ (accessed Oct 2017)

European surveillance network for vaccine-preventable diseases (EU-VAC.NET). Pertussis surveillance report 2008. 2010. Website [.euvac.net/graphics/euvac/pdf/pertussis_2008.pdf](http://euvac.net/graphics/euvac/pdf/pertussis_2008.pdf). Accessed February 2013.

European surveillance network for vaccine-preventable diseases (EU-VAC.NET). Pertussis surveillance annual report 2009. 21 January 2011a. website [.euvac.net/graphics/euvac/pdf/pertussis_2009.pdf](http://euvac.net/graphics/euvac/pdf/pertussis_2009.pdf). Accessed February 2013.

European surveillance network for vaccine-preventable diseases (EU-VAC.NET). Pertussis surveillance report 2010. 2011b. website [.euvac.net/graphics/euvac/pdf/pertussis_2010.pdf](http://euvac.net/graphics/euvac/pdf/pertussis_2010.pdf). Accessed February 2013.

Fine PE. Herd immunity: history, theory, practice. *Epidemiol Rev* 1993;15 (2):265–302.

Fisman DN, Tang P, Hauck T, Richardson S, Drews SJ, Low DE, Jamieson F. Pertussis resurgence in Toronto, Canada: a population-based study including test-incidence feedback modeling. *BMC Public Health*. 2011 Sep 7;11:694.

Fulton TR, Phadke VK, Orenstein WA, Hinman AR, Johnson WD, Omer SB. Protective Effect of Contemporary Pertussis Vaccines: A Systematic Review and Meta-analysis. *Clin Infect Dis*. 2016;62(9):1100-10.

Furuta M, Sin J, Ng ESW, Wang K.. Efficacy and safety of pertussis vaccination for pregnant women - a systematic review of randomised controlled trials and observational studies. *BMC Pregnancy Childbirth*. 2017 Nov 22;17(1):390.

Gall SA, Myers J, Pichichero M. Maternal immunization with tetanus-diphtheriapertussis vaccine: effect on maternal and neonatal serum antibody levels. *Am J Obstet Gynecol*. 2011; 204:334.e1–334.e5.

Gkentzi D, Katsakiori P, Marangos M, Hsia Y, Amirthalingam G, Heath PT, Ladhani S. Maternal vaccination against pertussis: a systematic review of the recent literature. *Arch Dis Child Fetal Neonatal Ed*. 2017 Sep;102(5):F456-F463.

Global Polio Eradication Initiative (GPEI). History of polio. 2010. ‘internet site’ [.polioeradication.org/Polioandprevention/Historyofpolio.aspx](http://polioeradication.org/Polioandprevention/Historyofpolio.aspx). Accessed 7 February 2013

Golaz A, Hardy IR, Strebel P, *et al*. Epidemic diphtheria in the Newly Independent States of the Former Soviet Union: implications for diphtheria control in the United States. *J Infect Dis* 2000;181 (Suppl 1):S237–S243.

Greco D, Salmaso S, Mastrantonio P, *et al*. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. *N Engl J Med* 1996; 334: 341–348.

Greece. Ministry of Health. Adult Vaccination Program 2017 (GMoH). Available at: ‘internet site’ ‘Internet site’://infovac.gr/wp-content/uploads/2016/12/EΘNIKO-ΠΡΟΓΡΑΜΑ-ΕΜΒΟΛΙΑΣΜΩΝ-ΠΑΙΔΙΩΝ-ΕΦΗΒΩΝ-907H465ΦΥΟ-2BΦ.pdf

Grgic-Vitek M, Klavs I, Kraigher A. Re-emergence of pertussis in Slovenia: time to change immunization policy. *Vaccine* 2008;26 (15):1874–1878.

Guiso N, Liese J, Plotkin S. The Global Pertussis Initiative: meeting report from the fourth regional roundtable meeting, France, April 14-15, 2010. *Hum Vaccin* 2011;7(4):481–488.

Hara M, Fukuoka M, Tashiro K, Ozaki I, Ohfuji S, Okada K, Nakano T, Fukushima W, Hirota Y. Pertussis outbreak in university students and evaluation of acellular pertussis vaccine effectiveness in Japan. *BMC Infect Dis.* 2015 Feb 6;15:45

Hardy-Fairbanks AJ, Pan SJ, Decker MD, Johnson DR, Greenberg DP, Kirkland KB, Talbot EA, Bernstein HH. Immune responses in infants whose mothers received dTpa vaccine during pregnancy. *Pediatr Infect Dis J.* 2013 Nov;32(11):1257-60.

He Q. *et al.*, on behalf of the European Bordetella expert group (EUpertstrain), the European surveillance network for vaccine-preventable diseases (EUVAC.NET). High heterogeneity in methods used for the laboratory confirmation of pertussis diagnosis among European countries, 2010: integration of epidemiological and laboratory surveillance must include standardisation of methodologies and quality assurance. *Euro Surveill.* 2012; 17(32): pii=20239
webiste.eurosurveillance.org/ViewArticle.aspx?ArticleId=20239

Health Council of the Netherlands (HCN). Vaccination against pertussis: aims and strategy. The Hague: Health Council of the Netherlands, 2015; publication no. 2015/29. available at: 'internet site'. gezondheidsraad.nl/sites/default/files/summary_201529_vaccinatie_tegen_kinkhoest_doel_en_strategie_0.pdf. Last accessed Dec. 2015.

Health Protection Agency (HPA). Questions and answers - Pertussis vaccination programme for pregnant women. 7 November 2012a. website
hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/WhoopingCough/ImmunisationForPregnantWomen/whoopingcoughandPertussisVaccinationProgrammeForPregnantWom/ Accessed February 2013.

Health Protection Agency (HPA). Whooping cough cases remain high. 21 December 2012b. website.hpa.org.uk/NewsCentre/NationalPressReleases/2012PressReleases/121221Whoopingcoughcasesremainhigh/. Accessed February 2013.

Health Protection Surveillance Centre (HPSC). Pertussis (whooping cough) outbreak - update December 2012. 10 December 2012. Website. hpsc.ie/hpsc/News/MainBody,13819,en.html. Accessed February 2013.

Health Service Executive (HSE), Ireland. Whooping cough vaccine for pregnant women. September 2014. 'internet site'. hse.ie/eng/health/immunisation/hcpinfo/OtherVaccines/pertussis/pertussisengleaf.pdf. Accessed November 2015.

Jackson DW, Rohani P. Perplexities of pertussis: recent global epidemiological trends and their potential causes. *Epidemiol Infect.* 2014 Apr;142(4):672-84.

Jardine A, Conaty SJ, Lowbridge C, *et al.*. Who gives pertussis to infants? Source of infection for laboratory confirmed cases less than 12 months of age during an epidemic, Sydney, 2009. *Commun Dis Intell* 2010; 34(2):116–121.

Joint Committee on Vaccination and Immunisation (JCVI). JCVI meeting on pertussis immunization: August 2012. Draft minutes of discussions on the immunization of pregnant women against pertussis. Published 28 September 2012. Website transparency.dh.gov.uk/2012/09/28/jcvi-pertussis/

Kamano H, Mori T, Maeta H, *et al.*. Analysis of Bordetella pertussis agglutinin titers during an outbreak of pertussis at a university in Japan. *Jpn J Infect Dis.* 2010 ; 63(2):108-12.

Keller-Stanislawski B, Englund JA, Kang G, Mangtani P, Neuzil K, Nohynek H, Pless R, Lambach P, Zuber P. Review safety of immunization during pregnancy: A review of the evidence of selected inactivated and live attenuated vaccines. *Vaccine.* 2014 Dec 12;32(52):7057-64.

Kharbanda EO, Vazquez-Benitez G, Lipkind HS, Klein NP, Cheetham TC, Naleway A, Omer SB, Hambidge SJ, Lee GM, Jackson ML, McCarthy NL, DeStefano F, Nordin JD. Evaluation of the association of maternal pertussis vaccination with obstetric events and birth outcomes. *JAMA.* 2014 Nov 12;312(18):1897-904.

Klein NP, Bartlett J, Fireman B, Rowhani-Rahbar A, Baxter R. Comparative effectiveness of acellular versus whole-cell pertussis vaccines in teenagers. *Pediatrics.* 2013;131(6).

Klein NP, Bartlett J, Fireman B, Baxter R. Waning Tdap Effectiveness in Adolescents. *Pediatrics.* 2016 Mar;137(3):e20153326.

Koepke R, Eickhoff JC, Ayele RA, Petit AB, Schauer SL, Hopfensperger DJ, Conway JH, Davis JP. Estimating the Effectiveness of Tdap Vaccine for Preventing Pertussis: Evidence of Rapidly Waning Immunity and Differences in Effectiveness by Tdap Brand. *J Infect Dis.* 2014 Sep 15;210(6):942-53.

Ladhani SN, Andrews NJ, Southern J, Jones CE, Amirthalingam G, Waight PA, England A, Matheson M, Bai X, Findlow H, Burbidge P, Thalasselis V, Hallis B, Goldblatt D, Borrow R, Heath PT, Miller E. Antibody Responses After Primary Immunization in Infants Born to Women Receiving a Pertussis-containing Vaccine During Pregnancy: Single Arm Observational Study With a Historical Comparator. *Clin Infect Dis.* 2015 Dec 1;61(11):1637-44.

Layton JB, Butler AM, Li D, Boggess KA, Weber DJ, McGrath LJ, Becker-Dreps S. Prenatal Tdap immunization and risk of maternal and newborn adverse events. *Vaccine.* 2017 Jul 24;35(33):4072-4078.

Leuridan E. Pertussis vaccination in pregnancy: State of the art. *Vaccine.* 2017 Aug 16;35(35 Pt A):4453-4456.

Loutan L. Vaccination of the immunocompromised patient. *Biologicals* 1997; 25:231-236.

Maertens K, Caboré RN, Huygen K, Hens N, Van Damme P, Leuridan E, et.al. Pertussis vaccination during pregnancy in Belgium: Results of a prospective controlled cohort study. *Vaccine*. 2016a; 34(1):142-50.

Maertens K, Caboré RN, Huygen K, Vermeiren S, Hens N, Van Damme P, Leuridan E. Pertussis vaccination during pregnancy in Belgium: Follow-up of infants until 1 month after the fourth infant pertussis vaccination at 15 months of age. *Vaccine*. 2016b Jun 30;34(31):3613-9. doi: 10.1016/j.vaccine. 2016b. 04.066. Epub 2016 Apr 30.

Maertens K, Burbidge P, van Damme P, Goldblatt D, Leuridan E. Pneumococcal Immune Response in Infants Whose Mothers Received Tdap Vaccination During Pregnancy. *Pediatr Infect Dis J*. 2017 Dec;36(12):1186-1192.

Manzanares S, Lafuente S, Martí M, *et al.*. Incidence of whooping cough in the city of Barcelona between 1999 and 2011. *Enfermedades Infecciosas y Microbiología Clínica* 2013; 31 (3): 156-58

Markina SS, Maksimova NM, Vitek CR, *et al.*. Diphtheria in the Russian Federation in the 1990s. *J Infect Dis* 2000;181(Suppl 1):S27–S34.

McMillan M, Clarke M, Parrella A, Fell DB, Amirthalingam G, Marshall HS. Safety of Tetanus, Diphtheria, and Pertussis Vaccination During Pregnancy: A Systematic Review. *Obstet Gynecol*. 2017 Mar;129(3):560-573.

Morgan JL, Baggari SR, McIntire DD, Sheffield JS. Pregnancy outcomes after antepartum tetanus, diphtheria, and acellular pertussis vaccination. *Obstet Gynecol*. 2015;125(6):1433-8.

New Zealand, Ministry of Health (NZMoH). Hospital-based Maternity Events 2007. Wellington: Ministry of Health; 2010: 'internet site'.health.govt.nz/publication/hospital-based-maternity-events-2007 ; accessed 23 October 2015.

New Zealand, Ministry of Health (NZMoH). Maternity Clinical Indicators 2013. Wellington: Ministry of Health; 2015: 'internet site'.health.govt.nz/publication/new-zealand-maternity-clinical-indicators-2013; accessed 23 October 2015.

Minor PD. The polio-eradication programme and issues of the end game. *J Gen Virol*. 2012 Mar; 93(Pt 3):457-74

MSSSI Spanish Ministry of Health - vaccination programme. Available at: 'internet site'.msssi.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/docs/Adenda_TosFerinaEmbarazo.pdf. Accessed August 2015

Munoz FM, Bond NH, Maccato M, Pinell P, Hammill HA, Swamy GK, Walter EB, Jackson LA, Englund JA, Edwards MS, Healy CM, Petrie CR, Ferreira J, Goll JB, Baker CJ. Safety and immunogenicity of tetanus diphtheria and acellular pertussis (Tdap) immunization during pregnancy in mothers and infants: a randomized clinical trial. *JAMA*. 2014 May 7;311(17):1760-9.

Murhekar M. Epidemiology of Diphtheria in India, 1996-2016: Implications for Prevention and Control. *Am J Trop Med Hyg.* 2017 ;97(2):313-318.

Murphy TV, Slade BA, Broder KR, Kretsinger K, Tiwari T, Joyce PM, Iskander JK, Brown K, Moran JS; Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC).. Prevention of pertussis, tetanus, and diphtheria among pregnant and postpartum women and their infants. Recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm Rep* 2008;57(RR-4):1–51.

Naidu MA, Muljadi R, Davies-Tuck ML, Wallace EM, Giles ML. The optimal gestation for pertussis vaccination during pregnancy: a prospective cohort study. *Am J Obstet Gynecol.* 2016 Aug;215(2):237.e1-6. doi: 10.1016/j.ajog.2016.03.002.

Nathanson N, Kew OM. From emergence to eradication: the epidemiology of poliomyelitis deconstructed. *Am J Epidemiol* 2010;172(11):1213–1229

New Zealand, Ministry of Health (NZMoH). Parents share their experiences of whooping cough. 10 December 2012. ‘internet site’ health.govt.nz/news-media/news-items/parents-share-theirexperiences-whooping-cough. Accessed 7 February 2013.

New Zealand, Pharmaceutical Management Agency (PHARMAC). Decision to amend the diphtheria, pertussis and tetanus vaccine (Boostrix) listing, 12 December 2012. Internet site: pharmac.govt.nz/2012/12/12/; accessed on 27 August 2014.

New Zealand, Ministry of health (NZMoH). Immunization Handbook 2017. Available at: ‘internet site’ ‘Internet site’: [://health.govt.nz/system/files/documents/publications/imm-handbook-funded-vaccines-for-special-groups-may17.pdf](http://health.govt.nz/system/files/documents/publications/imm-handbook-funded-vaccines-for-special-groups-may17.pdf) (accessed Sep 2017)

Nilsson L; Lepp T; von Segebaden K; Hallander H; Gustafsson L. Pertussis vaccination in infancy lowers the incidence of pertussis disease and the rate of hospitalisation after one and two doses: Analyses of 10 years of pertussis surveillance. *Vaccine.* 2012; 30 (21): 3239-47

Palmeira P, Quinello C, Silveira-Lessa AL, Zago CA, Carneiro-Sampaio M. IgG placental transfer in healthy and pathological pregnancies. *Clin Dev Immunol.* 2012;2012:985646.

Pan American Health Organization (PAHO). Epidemiological Alert. Pertussis (Whooping Cough). 16 November 2012. Website new.paho.org/hq/index.php?option=com_docman&task=doc_view&gid=19323&Itemid=. Accessed February 2013.

Philippines. Foundation for Vaccination, Adult Immunization Schedule (AIS) (2015). Available at: ‘internet site’ ‘Internet site’: [://philvaccine.org/vaccination-schedules/adult-immunization-schedule](http://philvaccine.org/vaccination-schedules/adult-immunization-schedule)

Petousis-Harris H, Walls T, Watson D, Paynter J, Graham P, Turner N. Safety of Tdap vaccine in pregnant women: an observational study. *BMJ Open.* 2016;18;6(4):e010911.

Potin M, Fica A, Véliz L, Moreno G, Wilhelm J, Cerda J. Strategies to protect the newborn and infants under 6 months of age against pertussis. *Rev Chilena Infectol* 2016; 33 (5): 543-546

Public Health Agency of Canada (PHAC). Available at: 'internet site' 'Internet site'://phac-aspc.gc.ca/publicat/cig-gci/p04-pertcoqu-eng.php (accessed Nov 2016).

Qatar Ministry of Health. MOPH. Tdap vaccine recommendations for pregnant women. Issued Feb 2017.

Roper K, Surveillance Branch, Office of Health Protection. Outbreak of pertussis, 1 January to 31 March 2009. *Commun Dis Intell Q Rep*, 2009 ; 33(1):36-7

Sáfadi MAP. Pertussis in young infants: a severe vaccine-preventable disease. *Autopsy Case Rep*. 2015; 5(2):1-4.

Sala-Farre MR, Arias-Varela C, Recasens-Recasens A, Simó-Sanahuja M, Muñoz-Almagro C, Pérez-Jové J. Pertussis epidemic despite high levels of vaccination coverage with acellular pertussis vaccine. *Enferm Infecc Microbiol Clin*. 2015 Jan;33(1):27-31.

Salmaso S, Mastrantonio P, Tozzi AE, Stefanelli P, Anemona A, Ciofi degli Atti ML, Giammanco A; Stage III Working Group. Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience. *Pediatrics* 2001;108(5):e81

Saul N, Wang K, Bag S, Baldwin H, Alexander K, Chandra M, Thomas J, Quinn H, Sheppard V, Conaty S. Effectiveness of maternal pertussis vaccination in preventing infection and disease in infants: The NSW Public Health Network case-control study. *Vaccine*. 2018 Mar 27;36(14):1887-1892.

Schmitt HJ, Schuind A, Knuf M, *et al*. Clinical experience of a tricomponent acellular pertussis vaccine combined with diphtheria and tetanus toxoids for primary vaccination in 22,505 infants. *J Pediatr*. 1996b;129:695-701.

Schmitt HJ, von König CH, Neiss A, *et al*. Efficacy of acellular pertussis vaccine in early childhood after household exposure. *JAMA*. 1996a;275:37-41.

Shakib JH, Korgenski K, Sheng X, Varner MW, Pavia AT, Byington CL. Tetanus, diphtheria, acellular pertussis vaccine during pregnancy: Pregnancy and infant health outcomes. *J Pediatrics*. 2013; 163: 5 (1422-1426.e4).

Sin MA, Zenke R, Rönckendorf R, *et al*. Pertussis outbreak in primary and secondary schools in Ludwigslust, Germany demonstrating the role of waning immunity. *Pediatr Infect Dis J* 2009;28(3):242–244.

Singapore. Ministry of Health (SMoH). National Adult immunisation schedule – Recommendations for adult vaccinations. MoH Circular 23/2017

Skoff TH, Blain AE, Watt J, Scherzinger K, McMahon M, Zansky SM, Kudish K, Cieslak PR, Lewis M, Shang N, Martin SW. Impact of the US Maternal Tetanus, Diphtheria, and Acellular Pertussis Vaccination Program on Preventing Pertussis in Infants <2 Months of Age: A Case-Control Evaluation. *Clin Infect Dis*. 2017 Nov 29;65(12):1977-1983.

Slovenia. National Institute of Public Health (NIJZ), Instructions for implementing immunization programme 2017. Available at: 'internet site' 'Internet site'://nijz.si/sites/nijz.si/files/uploaded/navodila_za_izvajanje_ip_2017.pdf (accessed Oct 2017)

Sukumaran L, McCarthy NL, Kharbanda EO, McNeil MM, Naleway AL, Klein NP, Jackson ML, Hambidge SJ, Lugg MM, Li R, Weintraub ES, Bednarczyk RA, King JP, DeStefano F, Orenstein WA, Omer SB. Association of Tdap Vaccination With Acute Events and Adverse Birth Outcomes Among Pregnant Women With Prior Tetanus-Containing Immunizations. *JAMA*. 2015a Oct 20;314(15):1581-7.

Sukumaran L, McCarthy NL, Kharbanda EO, Weintraub ES, Vazquez-Benitez G, McNeil MM, Li R, Klein NP, Hambidge SJ, Naleway AL, Lugg MM, Jackson ML, King JP, DeStefano F, Omer SB, Orenstein WA. Safety of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis and Influenza Vaccinations in Pregnancy. *Obstet Gynecol*. 2015b Nov;126(5):1069-74.

Taiwan, Ministry of Health and Welfare (MoHW). Infectious Disease Prevention and Control Group 103. Available at: 'internet site' 'Internet site'://61.57.41.133/downloadfile.aspx?fid=0AF604D3E0C0027A (accessed Sep 2017)

Tan T, Dalby T, Forsyth K, Halperin SA, Heininger U, Hozbor D, *et al.*. Pertussis Across the Globe: Recent Epidemiologic Trends From 2000 to 2013. *Pediatr Infect Dis J*. 2015;34(9):e222-32.

Tan T, Trindade E, Skowronski D. Epidemiology of pertussis. *Pediatr Infect Dis J* 2005;24(5 Suppl):S10–S18.

Thwaites CL, Yen LM. Tetanus. In: Warrell DA, Cox TM, Firth JD, eds. *Oxford Textbook of Medicine*. 5th edn. Oxford: Oxford University Press; 2010:Section 7.6.22.

Udwadia FE. Chapter 7.11.20: Tetanus. In: Warrell DA, Cox TM, Firth JD, eds. *Oxford Textbook of Medicine*, Volume 1. 4 edn. Oxford: Oxford University Press; 2003:545–551.

Vashishtha VM, Choudhury P, Kalra A, Bose A, Thacker N, Yewale VN, Bansal CP, Mehta PJ; Indian Academy of Pediatrics. Recommended Immunization Schedule for Children Aged 0 through 18 years – India, 2014 and Updates on Immunization. *Indian Pediatr*. 2014. 51(10):785-800

Vincent M, Rodeghiero C, Eylenbosch R, *et al.*. Pertussis serodiagnosis in Belgium from 1990 to 2009. *Clin Vaccine Immunol* 2011;18(4):588–594.

Vizzotti C, Neyro S, Katz N, Juárez MV, Perez Carrega ME, Aquino A, Kaski Fullone F. Maternal immunization in Argentina: A storyline from the prospective of a middle income country. *Vaccine*. 2015; 33(47):6413-9.

Vizzotti C, Juarez MV, Bergel E, Romanin V, Califano G, Sagradini S, Rancaño C, Aquino A, Libster R, Polack FP, Manzur J. Impact of a maternal immunization program against pertussis in a developing country. *Vaccine*. 2016 Dec 7;34(50):6223-6228.

Von König CH, Halperin S, Riffelmann M, Guiso N. Pertussis of adults and infants. *Lancet Infect Dis* 2002;2(12):744–750.

Walls T, Graham P, Petousis-Harris H, Hill L, Austin N. Infant outcomes after exposure to Tdap vaccine in pregnancy: an observational study. *BMJ Open*. 2016 Jan 6;6(1):e009536.

Wanlapakorn N, Maertens K, Chaithongwongwatthana S, Srimuan D, Suratannon N, Vongpunsawad S, Mai Phuong Tran T, Hens N, Van Damme P, Loch C, Poovorawan Y, Leuridan E. Assessing the reactogenicity of Tdap vaccine administered during pregnancy and antibodies to *Bordetella pertussis* antigens in maternal and cord sera of Thai women. *Vaccine*. 2018 Mar 7;36(11):1453-1459.

Ward JI, Cherry JD, Chang SJ, *et al.* Efficacy of an acellular pertussis vaccine among adolescents and adults. *N. Engl. J. Med.* 2005;353:1555-1563.

Wassilak SGF, Roper MH, Kretsinger K, Orenstein WA. Tetanus toxoid. In: Plotkin SA, Orenstein WA, Offit PA, eds. *Vaccines*. 5th edn. Philadelphia: Saunders Elsevier; 2008:805–839.

Wharton M, Vitek CR. Diphtheria toxoid. In: Plotkin SA, Orenstein WA, eds. *Vaccines*. 4th ed. Philadelphia: Saunders, 2008: pgs 211-228

Wiley KE, Zuo Y, Macartney KK, McIntyre PB. Sources of pertussis infection in young infants: a review of key evidence informing targeting of the cocoon strategy. *Vaccine* 2013; 31:618-25.

Winter K, Cherry JD, Harriman K. Effectiveness of Prenatal Tetanus, Diphtheria, and Acellular Pertussis Vaccination on Pertussis Severity in Infants. *Clin Infect Dis*. 2017a Jan 1;64(1):9-14.

Winter K, Nickell S, Powell M, Harriman K. Effectiveness of Prenatal Versus Postpartum Tetanus, Diphtheria, and Acellular Pertussis Vaccination in Preventing Infant Pertussis. *Clin Infect Dis*. 2017b Jan 1;64(1):3-8.

World Health Organisation (WHO) 2015b. “Polio case count” Retrieved 2015-10-31.

World Health Organization (WHO). Media centre. Poliomyelitis; fact sheets. 2018e. Website ‘Internet site’://who.int/mediacentre/factsheets/fs114/en/

World Health Organization (WHO). Summary of WHO Position Paper on Diphtheria Vaccines. August 2017a. Available at: 'internet site'://apps.who.int/immunization/policy/position_papers/diphtheria_summary.pdf

World Health Organization (WHO). Summary of WHO Position Paper on Tetanus Vaccines. February 2017b. Available at: 'internet site'://apps.who.int/iris/bitstream/handle/10665/254582/WER9206.pdf;jsessionid=CDAF6411D8D5E002783BBCDC4AB0FCE4?sequence=1. Accessed on April 2018.

World Health Organization (WHO). 2017c. Immunization, Vaccines and Biologicals, Vaccine and Disease, Tetanus. 'internet site'://apps.who.int.who.int/immunization/diseases/tetanus/en/. Accessed on 16 April 2018.

World Health Organization (WHO). 2017d. Immunization, Vaccines and Biologicals, Vaccine and Disease, Diphtheria. 'internet site'Internet site'://who.int/immunization/diseases/diphtheria/en/. Accessed on April 2018.

World Health Organization (WHO). Immunization, Vaccines and Biologicals. Diphtheria; surveillance and burden. 2017e. Website 'Internet site'://who.int/immunization/monitoring_surveillance/burden/diphtheria/en/. Accessed: April 2018.

World Health Organization (WHO), United Nations Children's Fund (UNICEF). WHO/UNICEF coverage estimates for 1980-2010, as of July 2012. October 2012. Website:who.int/immunization_monitoring/data/coverage_estimates_series.xls. Accessed February 2013.

World Health Organization (WHO), Position paper on Pertussis vaccines; September 2015. Wkly Epidemiol Rec. 2015a Aug 28;90(35):433-58.

World Health Organization (WHO). Pertussis vaccines: WHO position paper. Wkly Epidemiol Rec 2010a;85(40):385-400.

World Health Organization (WHO). Polio vaccines and polio immunization in the preeradication era: WHO position paper. Wkly Epidemiol Rec 2010b;85(23):213-228

World Health Organization (WHO). Global Immunization data. October 2012a. Website.who.int/immunization_monitoring/Global_Immunization_Data.pdf. Accessed July 2016.

World Health Organization (WHO). WHO vaccine-preventable diseases: monitoring system - 2012 global summary. Disease incidence. 2012b. Website apps.who.int/immunization_monitoring/en/globalsummary/timeseries/tsincidenceper.htm. Accessed February 2013.

World Health Organization (WHO). WHO Vaccine Preventable Diseases Monitoring System. Immunization schedules by antigen. 28 February 2018a. Website apps. 'Internet site'://apps.who.int/immunization_monitoring/globalsummary/schedules. Accessed April 2018.

World Health Organization (WHO). 2018b. WHO vaccine-preventable diseases: monitoring system - 2018 global summary. Disease incidence. 2018 Pertussis 'internet site':// 'Internet site'://apps.who.int/immunization_monitoring/globalsummary/timeseries/tsincidencepertussis.html. And internet site; 'Internet site'://who.int/immunization/monitoring_surveillance/burden/vpd/surveillance_type/passive/pertussis/en/. Accessed April 2018

World Health Organization (WHO). 2018c WHO vaccine-preventable diseases: monitoring system 2016 global summary. Disease incidence 2015 Diphtheria. 'internet site' 'Internet site'://apps.who.int/immunization_monitoring/globalsummary/timeseries/tsincidence-diphtheria.html. Accessed April 2018

World Health Organization (WHO). WHO vaccine-preventable diseases: monitoring system - 2017 global summary. Disease incidence. 2018d. Website 'Internet site'://apps.who.int/immunization_monitoring/globalsummary/incidences?c=GBR. Accessed April 2018

World Health Organization (WHO). Europe achieves historic milestone as Region is declared polio-free". Press release (European Region of the World Health Organization). 21 June 2002.

World Health Organization (WHO). Recommended standards for surveillance of selected vaccine-preventable diseases. 2003 - website: 'Internet site'://who.int/immunization/monitoring_surveillance/burden/vpd/surveillance_type/passive/pertussis_standards/en/. Accessed on april 2018.

World Health Organization (WHO). Tetanus vaccine. Wkly Epidemiol Rec 2006;81(20):198–208.

Yamazaki S; Toraya, H. (General News) Major Milestone reached in Global Polio Eradication: Western Pacific Region is certified Polio-Free. (2001) Health Educ. Res. 16 (1): 110.

Yeung KHT, Duclos P, Nelson EAS, Hutubessy RCW. An update of the global burden of pertussis in children younger than 5 years: a modelling study. Lancet Infect Dis. 2017;17(9):974-980.

Zepp F, Heining U, Mertsola J, *et al.* Rationale for pertussis booster vaccination throughout life in Europe. Lancet Infect Dis 2011;11(7):557–570.